President Benjamin R Yerxa buys 10,000 shares of Opus Genetics at $0.98; company faces steep -52.2% annual revenue decline and $7.5M loss.
Benjamin R Yerxa, as President of Opus Genetics, purchased 10,000 shares at $0.98 on 2024-11-21, increasing his holdings from 332,800 to 342,800 shares (+3.0%). The company is unprofitable, reporting a net income of $-7,526,000.00 and annual revenue growth of -52.2%, while trading on a recent listing (23 trading days). The purchase occurred at $0.98 against a current price of $1.10, a modest premium post-transaction. The context—significant revenue contraction and substantial operating losses—suggests operational headwinds that warrant scrutiny of the company's path to profitability, even as the President maintains equity exposure.